JenaValve tapped a medtech veteran with a string of successful exits behind him as interim chairman & CEO, replacing another medical device vet, David Drachman, after just 7 months.
JenaValve
TAVI: JenaValve adds $11m to Series C round
UPDATED Nov. 18, 2014, with a clarification from JenaValve.
JenaValve Technology yesterday reported adding nearly $17.3 million to a Series C funding round, bring the total raise to nearly $79.8 million.
Medtronic CEO Ishrak seeks to reassure employees on MDT-COV deal | The week in medtech M&A
Allergan CFO Edwards steps down amid hostile Valeant takeover bid | Personnel Moves
HeartWare nabs JenaValve exec Leadley for medical chief | Personnel Moves
JenaValve taps ex-AtriCure chief Drachman for CEO | Personnel Moves
TAVI: JenaValve lands expanded CE Mark for heart valve
JenaValve, fresh off of a $63 million funding round, said it won CE Mark approval in the European Union for its transapical replacement heart valve to treat aortic insufficiency, also known as aortic regurgitation.
The expanded approval makes JenaValve’s transcatheter aortic replacement valve implant the world’s only such device approved to treat high-risk or inoperable aortic insufficiency, according to a press release.
JenaValve treats 1st non-European patients with transaortic TAVI
A pair of Canadian women, aged 87 and 71, became the 1st non-European patients to receive treatment with JenaValve Technology‘s new transcatheter aortic valve implantation system.
JenaValve’s 2nd-generation transapical TAVI device is surgically implanted in the natural aortic valve cavity, and features an anchoring and clipping mechanism to ensure the device stays in place.
JenaValve raises $63M, eyes the U.S., China
JenaValve Technology said it plans to use a $62.5 million Series C round to expand its footprint in Europe and enter the transcatheter aortic heart implant markets in the U.S. and China.
Urologix names new CEO | Personnel Moves
Heart valves: Edwards Lifesciences, Medtronic to face stiffer competition
It’s not your father’s transcatheter aortic valve implant anymore.
Next year and the year after, the competitive landscape for TAVI will explode, with as many as 12 competing devices on the market here and across the pond.
And that competition will be fierce. As TAVI celebrates its 10th birthday,at least 1 analyst is predicting a 20%+ compound annual growth rate for the market, which she says could potentially double by 2015.